Public Reports - Suppression Cohort

The data presented in the following reports reflect the NNTC central database as of May 01, 2024

Usage Statement

Distribution of the data contained in this report through publication or presentation should be reported to the Data Coordinating Center. Reporting usage of the NNTC resources helps to ensure continuation of this valuable resource!

The NNTC is directly funded by the NIMH, NIA, NIDA, and NINDS.

Questions regarding these data should be directed to the Data Coordinating Center

The Emmes Company

Rockville, MD

nntc@emmes.com



Table of Contents

Suppressed Cohort Overview: PWH

Cohort Enrollment & Study Status

CNS Specimens Available

Peripheral Specimens Available

Fluids Available (%)

Demographics

cART Era Demographics

HIV Characteristics

cART Era Viral Load

Pathological Conditions: Year of Autopsy

Last Psychiatric Diagnosis

Baseline Psychiatric Diagnosis

Cognitive Diagnosis (%)

Change in Cognitive Diagnosis

Neurologic Diagnoses

Concomitant Medications

Ancillary Lab Measurements


Click on a content link to navigate to the corresponding slide. To return to the Table of Contents from anywhere in the report, click on the NNTC logo found on each slide in the upper left corner.



Suppression Cohort Overview



Suppression Cohort Overview



Criteria 1: Participants have been followed for at least 5 years. There must be at least 1 undetectable viral load within last 1 year, or 2 undetectable viral loads within last 2. Over last 5 year period, there must be at least 4 undetectable viral loads. Note that "blips" of detectable virus are allowed, however these must be <1000 copies/mL during this 5 year period.

Criteria 2: Participants have been followed for at least 2 years. There must be at least 1 undetectable viral load within last 6 months. Note that "blips" of detectable virus are allowed, however these must be <1000 copies/mL during this 2 year period.

Longitudinal Cohort: Participants enrolled with 2 or more study visits.

Tissue Bank: Participants deceased with autopsy.

63 cases meet both criteria. 29 autopsy cases met both criteria.

Inactive cases are either lost to follow-up/administratively censored/withdrawn (N=21) or deceased without autopsy (N=23).

^{* 0} autopsy cases included in Cross Sectional Cohort; 38 autopsy cases included in Longitudinal Cohort.

^{^0} autopsy cases included in Cross Sectional Cohort; 71 autopsy cases included in Longitudinal Cohort.



CNS Specimens Available

Type:	PWH
Frozen Brain	75
Fixed Brain	72
Spinal Cord	72
Cerebellum*	62
Brain Stem*	61
Frontal Lobe*	57
Parietal Lobe*	56
Occipital Lobe*	56
Temporal Lobe*	56
Thalamus*	55
Basal Ganglia*	52
Dorsal Root Ganglia	51
Hippocampus*	48
Trigerminal Ganglia	24

^{*}Several of the smaller brain categories listed were approved by the Steering Committee on 27JUN2017 to be reported centrally, and thus are currently underreported in the central inventory as sites work towards retrospectively updating specimen records. It is expected that the central inventory, including availability of these specimens, will continue to be updated prospectively.

Olimay2024




Peripheral Organ Specimens Available

Type:	PWH
Heart	73
Liver	72
Spleen	69
Kidney	66
Lung	66
Peripheral Nerve	62
Adipose Tissue	55
Bone Marrow	54
Muscle	54
Lymph Node	51
Bowel	39
Pituitary Gland	30
Testes	28
Hair	4
Thymus	1



Available Fluids



^{*}All-combinations (e.g., one specimen might be available ante-mortem while the other two might be ante- and post-mortem or any of the other 23 combinations where all 3 specimen availabilities are not the same).

Please note the totals listed above reflect only those cases who have a fixed brain specimen available and fluids collected within 1 year of death. Percentage labels not shown are 2% or less.

01MAY2024



Demographics*

<u>N</u>	72
Age	
Mean	60.8
SD	9
25th Percentile	55
Median	59.5
75th Percentile	66.5

^{*}Cases with a fixed brain specimen available with a measurement at baseline and within 1 year of death.



Demographics cont.*

	<u>N</u>	<u>%</u>
Gender		
Male	54	75
Female	18	25
Ethnicity Hispanic origin	21	29
Race		
White	35	49
Black	29	40
Other	8	11

^{*}Cases with a fixed brain specimen available.




Demographics cont.*

	N	<u>%</u>
Furthest Education		
8th grade or less	4	6
Some High School	18	25
High School Gradudate	17	24
Some College/Associate's Degree	21	29
College Graduate	5	7
Advanced Degree work	7	10

^{*}Cases with a fixed brain specimen available.




cART Era Demographics - Gender



^{*}The NNTC did not collect data before 1998.



cART Era Demographics - Race



^{*}The NNTC did not collect data before 1998.



HIV Characteristics of autopsy cases*

	<u>N</u>	<u>%</u>
Baseline HIV risk		
IV drug use	24	33
Male to male sex	32	44
Heterosexual sex	16	22
On ART		
at baseline	70	97
at last visit	65	90

^{*}Cases with a fixed brain specimen available.



HIV Characteristics at time of death*

CD4 Count (N=66)

25th Percentile	197
Median	369
75th Percentile	572

Log Plasma Viral Load** (N=67)

25th Percentile	1.30
Median	1.60
75th Percentile	1 70


^{*}Cases with a fixed brain specimen available with a measurement at baseline and within 1 year of death.

^{**}Among those with known ARV medication status. 3 participants had detectable VL values of 0 where a viral log could not otherwise be calculated.

01MAY2024



cART Era Viral Load



^{*}Among those who have died during the cART era.




Pathological Conditions: Year of Autopsy

	Year of Autopsy		
Type:	< 2010	2010-present	Total Cases
Total Fixed Specimens	18	54	72
Normal/minor neuropath changes	5 (28)	7 (13)	12 (17)
Other non-infectious pathology	6 (33)	28 (53)	34 (47)
Alzheimer's type 2 gliosis	1 (6)	8 (15)	9 (13)
Focal infarct	7 (39)	18 (34)	25 (35)
Hypoxic/ischemic damage	4 (22)	15 (28)	19 (26)
Aseptic Leptomeningitis	2 (11)	9 (17)	11 (15)
Microglial nodule encephalitis	0	1 (2)	1 (1)
Hemorrhage-parenchymal	0	6 (11)	6 (8)
Progressive Multifocal Leukoencephalopathy	0	1 (2)	1 (1)
Other infections	0	3 (6)	3 (4)



Last Psychiatric Diagnosis



Psychiatric Diagnosis: Dependence or Abuse


■ Current or Current+Past ■ Past Only

63% are Normal/Test Not Administered

*Please note the totals listed above reflect only those cases who have a fixed brain specimen available and data from the PRISM/CIDI evaluation before death.



Baseline Psychiatric Diagnosis



Psychiatric Diagnosis: Dependence or Abuse


■ Current ■ Past only

17% are Normal/Test Not Administered

*Please note the totals listed above reflect only those cases who have a fixed brain specimen available and data from the PRISM/CIDI evaluation closest to baseline.



Cognitive Diagnosis



Cognitive Diagnosis

■ Baseline (N=71) ■ Last Diagnosis (N=50)

ANI = Asymptomatic Neurocognitive Impairment

MCMD = Minor Cognitive Motor Disorder

MND = Minor Neurocognitive Disorder


HAD = HIV-Associated Dementia

NPI-O = Neuropsychological Impairment - Other cause, not HIV

^{*}Please note the totals listed above reflect only those cases who have a fixed brain specimen available.



Change in Cognitive Diagnosis



Baseline Diagnosis





Neurologic Diagnoses*

	Las	Last Dx		Baseline	
	<u>N</u>	<u>%</u>	<u>N</u>	<u>%</u>	
Clinical Myelopathy	<u>(</u> N=	49)	<u>(</u> N=	- 71)	
HIV associated	4	8	5	7	
Other	0	0	2	3	
None	45	92	64	90	
Neuropathy	(N=	-43)	(N=	- 60)	
HIV associated DSP	30	70	28	47	
HIV/nucleoside	4	9	4	7	
None	9	21	28	47	

^{*}Cases with a fixed brain specimen available.



Participants Reporting Concomitant Medications

Medication	# of Pts (N=71)	%
Central Nervous System Agents	68	95.8
Cardiovascular Drugs	63	88.7
Gastrointestinal Drugs	63	88.7
Vitamins	60	84.5
Anti-infective Agents	57	80.3
Hormones and Synthetic Substitutes	49	69
Electrolytic, Caloric, and Water Balance	47	66.2
Autonomic Drugs	46	64.8
Skin and Mucous Membrane Agents	38	53.5
Blood Formation, Coagulation, and Thrombosis Agents	35	49.3
Miscellaneous Therapeutic Agents	29	40.8
Eye, Ear, Nose, and Throat (EENT) Preparations	27	38
Antihistamine Drugs	26	36.6
Respiratory Tract Agents	20	28.2
Antineoplastic Agents	18	25.4
Pharmaceutical Aids	8	11.3
Local Anesthetics	7	9.9
Serums, Toxoids, and Vaccines	6	8.5
No medication use reported on at least one occasion	5	7
Smooth Muscle Relaxants	5	7



Ancillary Lab Measurements

Ancillary Lab	Total # records overall	% cohort with at least 1 measure	Total # cases with baseline measure	% cohort with baseline & one other measure
Miscellaneous Hematology				
Red blood cells	196	13	3	4
Mean Corpuscular Hemoglobin (MCH)	195	13	3	4
Mean Corpuscular Volume (MCV)	1202	69	44	61
Mean Corpuscular Hemoglobin Concentration (MCHC)	188	11	3	4
Blood Red cell Distribution Width (RDW)	194	13	3	4
Blood Rapid Plasma Reagin (RPR)	208	71	28	26
Blood Neutrophil Percent	1157	68	44	61
Blood Lymphocyte Percent	1171	68	44	61
Blood Monocyte Percent	1158	68	44	61
Blood Eosinophil Percent	1156	68	44	61
Blood Basophil Percent	1154	68	44	61
Blood Mean Platelet Volume (MPV)	151	8	3	4
Blood CD3 Percent	11	3	1	0
Blood CD3 Absolute	11	3	1	0
Miscellaneous Serology & viral loads				
Blood Hepatitis B Surface Antigens	131	71	38	31
Blood Hepatitis B Surface Antibodies	112	60	30	26
Blood Hepatitis B Core Antibodies	112	63	31	24
Blood Hepatitis B Viral Load	20	11	3	3
Blood Hepatitis C Antibodies (HCV)	171	85	47	39
Blood Hepatitis C Viral Load	81	40	12	14
Miscellaneous Serology & viral loads				
COVID-19 Test Results (qualitative)	23	11	0	0



Ancillary Lab Measurements cont.

Ancillary Lab	Total # records overall	% cohort with at least 1 measure	Total # cases with baseline measure	% cohort with baseline & one other measure		
Miscellaneous Blood Chemistries						
Glucose	1125	68	44	61		
Hemoglobin A1c	265	65	14	17		
Sodium	1080	74	44	61		
Calcium	1027	67	42	58		
Chloride	1055	74	42	58		
Potassium	1064	74	42	58		
Total Protein	898	72	40	56		
Alkaline Phosphatase	897	68	40	56		
AST	882	68	38	53		
ALT	897	68	40	56		
Total Bilirubin	943	75	44	61		
Direct Bilirubin	57	7	1	1		
Creatinine	1283	93	55	74		
BUN	1072	72	42	58		
CO2	1048	68	42	58		
PT	564	64	41	57		
INR	563	64	41	57		
Urate	10	6	1	0		
Triglycerides	383	76	26	33		
Cholesterol	389	76	27	35		
LDL	358	72	25	31		
HDL	367	75	27	33		
Phosphorus	85	10	2	1		
LDH	15	6	1	0		



Ancillary Lab Measurements cont.

Ancillary Lab	Total # records overall	% cohort with at least 1 measure	Total # cases with baseline measure	% cohort with baseline & one other measure		
Miscellaneous CSF values						
CSF-VDRL Test	34	8	3	4		
Miscellaneous Urine values						
Urinalysis: Glucose	461	63	40	53		
Urinalysis: Protein	466	63	40	53		
Urinalysis: pH	462	63	40	53		
Urinalysis: Specific Gravity	461	63	40	53		
Urinalysis: Ketones	460	61	40	53		
Urinalysis: Bilirubin	461	63	40	53		
Urine Toxicology; Methamphetamine	77	13	6	8		
Urinalysis: Red Blood Cells	259	53	23	29		
Urinalysis: White Blood Cells	255	53	23	29		